Preventing diabetic complications: A primary care perspective

Diabetes Research and Clinical Practice

Volumn 84, Issue 2, 2009, Pages 107-116

  Zimmet, Paul ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Cardiometabolic risk factors; Diabetes; Diabetic retinopathy; Fenofibrate; Preventive medicine

Indexed keywords

FENOFIBRATE; INSULIN; METFORMIN; PIOGLITAZONE; SULFONYLUREA;

CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC RETINOPATHY; DIET THERAPY; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY MEDICAL CARE; QUALITY OF LIFE; REVIEW;

ANTILIPEMIC AGENTS; COST OF ILLNESS; DIABETES COMPLICATIONS; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIABETIC NEUROPATHIES; DIABETIC RETINOPATHY; HUMANS; MICROCIRCULATION; PREVALENCE; PRIMARY HEALTH CARE; PROCETOFEN; QUALITY OF LIFE; RISK FACTORS;

EID: 63649120214     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2009.01.016     Document Type: Review

References (78)

1. Sicree R. Diabetes Atlas. Third edition (2008), International Diabetes Federation, Brussels
2. World Health Organisation and International Diabetes Federation, Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia, Available at www.idf.org/webdata/docs/WHO_IDF_definition_diagnosis_of_diabetes.pdf (accessed June 15, 2008).
3. Alberti K.G.M.M., Zimmet P., and Shaw J. International Diabetes Federation: a consensus on type 2 diabetes prevention. Diabet. Med. 24 (2007) 451-463
4. Nathan D.M., Davidson M.B., DeFronzo R.A., Heine R.J., Henry R.R., Pratley R., et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 30 (2007) 753-759
5. Gerstein H.C., Santaguida P., Raina P., Morrison K.M., Balion C., Hunt D., et al. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res. Clin. Pract. 78 (2007) 305-312
6. Haffner S.M. Abdominal obesity, insulin resistance, and cardiovascular risk in pre-diabetes and type 2 diabetes. Eur. Heart J. Suppl. 8 Suppl. B (2006) B20-B25
7. Lee C.M., Huxley R.R., Wildman R.P., and Woodward M. Indices of abdominal obesity are better discriminators of cardiovascular risk factors than BMI: a meta-analysis. J. Clin. Epidemiol. 61 (2008) 646-653
8. Freemantle N., Holmes J., Hockey A., and Kumar S. How strong is the association between abdominal obesity and the incidence of type 2 diabetes?. Int. J. Clin. Pract. (2008) (advance publication online)
9. Ford E.S., Giles W.H., and Mokdad A.H. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 27 (2004) 2444-2449
10. Yoon K.H., Lee J.H., Kim J.W., Cho J.H., Choi Y.H., Ko S.H., et al. Epidemic obesity and type 2 diabetes in Asia. Lancet 368 (2006) 1681-1688
11. Zimmet P., Alberti K.G., and Shaw J. Global and societal implications of the diabetes epidemic. Nature 414 (2001) 782-787
12. Levitt N. Diabetes in Africa: Epidemiology, management and healthcare challenges. Heart (2008) (advance publication online)
13. Ramachandran A., Mary S., Yamuna A., Murugesan N., and Snehalatha C. High prevalence of diabetes and cardiovascular risk factors associated with urbanization in India. Diabetes Care 31 (2008) 893-898
14. Stamler J., Vaccaro O., Neaton J.D., and Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16 (1993) 434-444
15. Haffner S.M., Lehto S., Rönnemaa T., Pyörälä K., and Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 339 (1998) 229-234
16. Gu K., Cowie C.C., and Harris M.I. Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993. Diabetes Care 21 (1998) 1138-1145
17. Huxley R., Barzi F., and Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 332 (2006) 73-78
18. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
19. Juutilainen A., Lehto S., Rönnemaa T., Pyörälä K., and Laakso M. Type 2 diabetes as a "coronary heart disease equivalent": an 18-year prospective population-based study in Finnish subjects. Diabetes Care 28 (2005) 2901-2907
20. González-Clemente J.M., Palma S., Arroyo J., Vilardell C., Caixàs A., Giménez-Palop O., et al. Is diabetes mellitus a coronary heart disease equivalent? Results of a meta-analysis of prospective studies. Rev. Esp. Cardiol. 60 (2007) 1167-1176 (Spanish)
21. Evans J.M., Wang J., and Morris A.D. Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. BMJ 324 (2002) 939-942
22. Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD), Guideline on diabetes, pre-diabetes, and cardiovascular diseases: full text. Available at www.escardio.org (accessed June 15, 2008).
23. Barr E.L., Zimmet P.Z., Welborn T.A., Jolley D., Magliano D.J., Dunstan D.W., et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian diabetes, obesity, and lifestyle study (AusDiab). Circulation 116 (2007) 151-157
24. Tuomilehto J., Rastenyte D., Qiao Q., and Jakovljevic D. Epidemiology of macrovascular disease and hypertension in diabetes mellitus. In: De Fronso R.A., Ferrannini E., Keen H., and Zimmet P. (Eds). International Textbook of Diabetes Mellitus. 3rd edition (2004), John Wiley & Sons, Milan 1345-1370
25. Portuese O., and Orchard T. Mortality in insulin dependent diabetes. Diabetes in America. 2nd edition (1995), National Institutes of Health and National Institute for Diabetes, Digestive and Kidney disorders, Bethesda MD pp. 221-232
26. Wiernsperger N.F., and Bouskela E. Microcirculation in insulin resistance and diabetes: more than just a complication. Diabetes Metab. 29 6 (2003) S77-S87
27. Juutilainen A., Lehto S., Rönnemaa T., Pyörälä K., and Laakso M. Retinopathy predicts cardiovascular mortality in type 2 diabetic men and women. Diabetes Care 30 (2007) 292-299
28. Cheung N., Wang J.J., Klein R., Couper D.J., Sharrett A.R., and Wong T.Y. Diabetic retinopathy and the risk of coronary heart disease. The Atherosclerosis Risk in Communities study. Diabetes Care 30 (2007) 1742-1746
29. UKPDS Study Group. Complications in newly diagnosed type 2 diabetic patients and their association with different clinical and biochemical risk factors. Diabetes Res. 13 (1990) 1-11
30. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
31. A. Keech, R.J. Simes, P. Barter, J. Best, R. Scott, M.R. Taskinen, et al., on behalf of the FIELD study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005) 1849-1861.
32. Ciulla T.A., Amador A.G., and Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care 26 (2003) 2653-2664
33. National Institute of Diabetes and Digestive and Kidney Diseases, National Diabetes statistics, Available at http://diabetes.niddk.nih.gov/dm/pubs/statistics/index.htm (accessed June 15, 2008).
34. Center for Disease Control. Prevalence of visual impairment and selected eye diseases among persons aged >50 years with and without diabetes-United States, 2002. MMWR Weekly 53 (2004) 1069-1071
35. Diabetes Prevention Program Research Group. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabet. Med. 24 (2007) 137-144
36. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance, Diabetologia 34 (1991) 877-890.
37. National Institute of Diabetes and Digestive and Kidney Diseases, Kidney disease of diabetes, Available at http://kidney.niddk.nih.gov/kudiseases/pubs/kdd/index.htm (accessed June 15, 2008).
38. Molitch M.E., DeFronzo R.A., Franz M.J., Keane W.F., Mogensen C.E., Parving H.H., et al. Nephropathy in diabetes. Diabetes Care 27 Suppl. 1 (2004) S79-S83
39. Datamonitor Market Brief, Diabetic nephropathy prevalence, progression, prevention and potential (2003), Summary available at http://www.datamonitor.com/Products/Free/Brief/BFHC0625/010BFHC0625.pdf (accessed June 17, 2008).
40. Pavkov M.E., Knowler W.C., Hanson R.L., Bennett P.H., and Nelson R.G. Predictive power of sequential measures of albuminuria for progression to ESRD or death in Pima Indians with type 2 diabetes. Am. J. Kidney Dis. 51 (2008) 759-766
41. Pavkov M.E., Krakoff J., Sievers M.L., and Nelson R.G. Effect of youth-onset type 2 diabetes mellitus on incidence of end-stage renal disease and mortality in young and middle-aged Pima Indians. JAMA 296 (2006) 421-426
42. National Institute of Diabetes and Digestive and Kidney Diseases, Diabetic neuropathies: the nerve damage of diabetes, Available at http://diabetes.niddk.nih.gov/dm/pubs/neuropathies/index.htm (accessed June 17, 2008).
43. American Diabetes Association, Complications of diabetes in the United States, Available at http://www.diabetes.org/diabetes-statistics/complications.jsp (accessed June 19, 2008).
44. Fagot-Campagna A., Bourdel-Marchasson I., and Simon D. Burden of diabetes in an aging population: prevalence, incidence, mortality, characteristics and quality of care. Diabetes Metab. 31 Suppl. 2 (2005) 5S35-5S52
45. Holmes J., McGill S., Kind P., Bottomley J., Gillam S., and Murphy M. Health-related quality of life in type 2 diabetes (TARDIS-2). Value Health 3 Suppl. 1 (2000) 47-51
46. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care 31 (2008) 1-20
47. Nichols G.A., Glauber H.S., and Brown J.B. Type 2 diabetes: incremental medical care costs during the 8 years preceding diagnosis. Diabetes Care 23 (2000) 1654-1659
48. Brown J.B., Nichols G.A., Glauber H.S., and Bakst A.W. Type 2 diabetes: incremental medical care costs during the first 8 years after diagnosis. Diabetes Care 22 (1999) 1116-1124
49. Bagust A., Hopkinson P.K., Maslove L., and Currie C.J. The projected health care burden of Type 2 diabetes in the UK from 2000 to 2060. Diabet. Med. 19 Suppl 4 (2002) 1-5
50. Gray A., Raikou M., McGuire A., Fenn P., Stevens R., Cull C., et al. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study Group. BMJ 320 (2000) 1373-1378
51. Clarke P., Gray A., Adler A., Stevens R., Raikou M., Cull C., et al. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51). Diabetologia 44 (2001) 298-304
52. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care 31 Suppl 1 (2008) S12-S54
53. International Diabetes Federation, Clinical Guidelines Task Force, Global Guideline for Type 2 Diabetes 2005, Available at http://www.idf.org (accessed June 20, 2008).
54. UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
55. UK Prospective Diabetes Study Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998) 854-865
56. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 358 (2008) 2545-2559
57. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 358 (2008) 2560-2572
58. Lachin J.M., Genuth S., Nathan D.M., Zinman B., Rutledge B.N., and DCCT/EDIC Research Group. Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial-revisited. Diabetes 57 (2008) 995-1001
59. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329 (1997) 977-986
60. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317 (1998) 703-713
61. ADVANCE Collaborative Group, Patel A., MacMahon S., Chalmers J., Neal B., Woodward M., et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370 (2007) 829-840
62. Gaede P., Vedel P., Larsen N., Jensen G.V., Parving H.H., and Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med. 348 (2003) 383-393
63. Colhoun H.M., Betteridge D.J., Durrington P.N., Hitman G.A., Neil H.A., Livingstone S.J., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
64. Keech A.C., Mitchell P., Summanen P.A., O'Day J., Davis T.M., Moffitt M.S., et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 370 (2007) 1687-1697
65. UK Prospective Diabetes Study Group, UKPDS Post Study Monitoring Programme, Available at http://www.dtu.ox.ac.uk/ukpds/psm.php (accessed June 20, 2008).
66. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group, Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study, JAMA 290 (2003) 2159-2167.
67. Nathan D.M., Cleary P.A., Backlund J.Y., Genuth S.M., Lachin J.M., Orchard T.J., et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N. Engl. J. Med. 353 (2005) 2643-2653
68. Gaede P., Lund-Andersen H., Parving H.H., and Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N. Engl. J. Med. 358 (2008) 580-591
69. Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney P.M., Blackwell L., Collins R., Keech A., Simes J., et al. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371 (2008) 117-125
70. Bruckert E., Baccara-Dinet M., and Eschwege E. Low HDL-cholesterol is common in European Type 2 diabetic patients receiving treatment for dyslipidaemia: data from a pan-European survey. Diabet. Med. 24 (2007) 388-391
71. Koopman R.J., Mainous III A.G., Diaz V.A., and Geesey M.E. Changes in age at diagnosis of type 2 diabetes mellitus in the United States, 1988 to 2000. Ann. Fam. Med. 3 (2005) 60-63
72. Hoerger T.J., Segel J.E., Gregg E.W., and Saaddine J.B. Is glycemic control improving in U.S. adults?. Diabetes Care 31 (2008) 81-86
73. Imperatore G., Cadwell B.L., Geiss L., Saadinne J.B., Williams D.E., Ford E.S., et al. Thirty-year trends in cardiovascular risk factor levels among US adults with diabetes: National Health and Nutrition Examination Surveys, 1971-2000. Am. J. Epidemiol. 160 (2004) 531-539
74. Gregg E.W., Gu Q., Cheng Y.J., Narayan K.M., and Cowie C.C. Mortality trends in men and women with diabetes, 1971-2000. Ann. Intern. Med. 147 (2007) 149-155
75. Fox C.S., Coady S., Sorlie P.D., D'Agostino Sr. R.B., Pencina M.J., Vasan R.S., et al. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation 115 (2007) 1544-1550
76. Scott R., Best J., Forder P., Taskinen M.R., Simes J., Barter P., et al. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]. Cardiovasc. Diabetol. 4 (2005) 13
77. D. Burgess, D. Hunt, L.P. Li, J. Zhang, R. Sy, M. Laakso, et al., on behalf of the FIELD Investigators. Effects of fenofibrate on silent myocardial infarction, hospitalization for acute coronary syndromes and amputation in type 2 diabetes: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, Circulation 116 (2007) II_838 (abstract).
78. Scott R., O'Brien R., Fulcher G., Pardy C., d'Emden M., Tse D., et al. The effects of fenofibrate treatment on cardiovascular disease risk in 9795 people with type 2 diabetes and various components of the metabolic syndrome: the FIELD study. Diabetes Care (2008) (published on-line ahead of print November 4, 2008)